Can febuxostat (Uloric) be discontinued if symptoms of gout are stable?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Febuxostat should not be stopped even if gout symptoms are stable, as discontinuing the medication can lead to a rebound increase in uric acid levels, triggering new gout attacks. The medication is intended for long-term use to maintain uric acid levels below the target of 6.0 mg/dL and prevent future gout flares. Some key points to consider:

  • Discontinuing febuxostat can lead to a rebound increase in uric acid levels, which can trigger new gout attacks, even after a period of symptom stability 1.
  • The absence of symptoms does not mean the underlying hyperuricemia has resolved, and periodic uric acid monitoring may be necessary to ensure levels remain controlled 1.
  • Some patients with years of well-controlled uric acid levels and no tophi (urate deposits) might eventually discuss dose reduction with their doctor, but complete discontinuation is generally not recommended 1.
  • The medication works by inhibiting xanthine oxidase, the enzyme responsible for uric acid production, addressing the root cause of gout rather than just treating symptoms 1. It is essential to consult with a healthcare provider before stopping febuxostat, as they may recommend periodic uric acid monitoring to ensure levels remain controlled.

From the Research

Stopping Febuxostat for Stable Symptoms

  • There is no direct evidence in the provided studies to suggest that febuxostat can be stopped if symptoms are stable 2, 3, 4, 5, 6.
  • However, long-term treatment with febuxostat for up to 4 years or more has been shown to reduce the incidence of gout flares to (or close to) zero 3.
  • Sustained reduction in serum uric acid level with febuxostat therapy has been associated with near elimination of gout flares and improved tophus status 4.
  • The decision to stop febuxostat should be made on a case-by-case basis, taking into account the individual patient's response to treatment and potential risks of stopping therapy.
  • It is essential to monitor patients for signs and symptoms of myocardial infarction and stroke, as well as liver function abnormalities, when stopping febuxostat 2, 5.

Considerations for Stopping Febuxostat

  • Patients with stable symptoms may still require ongoing treatment to maintain serum uric acid levels below 6 mg/dL 3, 4.
  • Stopping febuxostat may lead to an increase in serum uric acid levels, potentially resulting in gout flares or other complications 3, 4.
  • The safety and efficacy of stopping febuxostat have not been extensively studied, and more research is needed to determine the optimal treatment duration and discontinuation strategy 2, 3, 4, 5, 6.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Febuxostat for treatment of chronic gout.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2011

Research

Febuxostat.

Drugs, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.